HHS & Healthcare Contracts Intelligence — May 13, 2026

Bavarian Nordic A/S received a $1,264,240,981 contract from Department of Health and Human Services on 2017-08-24, the highest materiality (8/10) award driving 80% of period's total obligations.

Albert B. Sabin Vaccine Institute, Inc. has $163,082,415 obligated under a cost-plus-fixed-fee contract (ceiling $240,940,070) for Sudan Ebolavirus vaccine manufacturing through 2030-09-30, with $62,167,518 outlayed.

Albert B. Sabin Vaccine Institute, Inc.'s $147,062,009 cost-no-fee contract for Marburg and Sudan Ebolavirus vaccines has $88,575,804 outlayed through 2027-09-30 under base + options of $149,747,956.

Albert B. Sabin Vaccine Institute, Inc. holds 20% of total obligations ($310M across two contracts), but as a tax-exempt nonprofit, offers no direct equity exposure despite low pricing risk.

Bavarian Nordic A/S $1.26B contract lacks data on annual revenue impact, pricing risk, or competition, limiting quantifiable upside assessment.

Albert B. Sabin Vaccine Institute, Inc. options exercisable toward $240,940,070 and $149,747,956 ceilings on BARDA/ASPR vaccine contracts.

Bavarian Nordic A/S $1.26B HHS award signals potential for follow-on biotech preparedness work.

Three contracts totaling $1.57B fund biotech R&D and manufacturing for Sudan Ebolavirus and Marburg vaccines via full and open competition under NAICS 541714, with $150M+ outlayed across Sabin awards.

{"entity"=>"Albert B. Sabin Vaccine Institute, Inc.", "reason"=>"$310M in dual BARDA contracts with $150M outlayed and options to $390M total ceiling", "trigger"=>"option exercise toward $240M and $149.7M ceilings"}

{"entity"=>"Bavarian Nordic A/S", "reason"=>"$1.26B HHS award comprising 80% of period obligations", "trigger"=>"outlay progress or contract modifications"}

{"entity"=>"BARDA/ASPR", "reason"=>"Funding two Sabin contracts for Ebolavirus/Marburg vaccines through 2030", "trigger"=>"outlay beyond $62M and $88M"}